I take the simple way out and like to believe the letter was on behalf of Incyte protecting their market space, the USA for their one and only product.
Pediatric aGVHD is the thin end of the wedge, adult and chronic is much more profitable and that is what they have currently or would be able to move into with nil competition.
MSB to dispute FDA finding in Type A meeting, page-770
-
- There are more pages in this discussion • 248 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |